Market Intelligence Signals
Thread 5 — Oncology US market · disruption & risk signals with feature explainability
199 drug × indication signals
66 high disruption signals
Updated 2026-09-20
What this page is — and is not
This week's analysis
Model Review Agent · 2026-09-20
Overview

This week's models run across 199 drug-indication pairs but only 5 of 9 features have any data — NIH funding momentum, publication velocity, patent cliff proximity, and CMS spend trajectory are entirely null. The approval model achieves high CV AUC (0.92) but is effectively a single-feature threshold on prior approval count, not a nuanced signal. The disruption model is similarly concentrated, driven almost entirely by approval count and shortage risk score. Revenue trajectory is directional only due to the 2yr CMS data lag, and the CMS feature is null this cycle. These predictions are structural signals about where regulatory momentum and competitive density are concentrating — not forecasts. The Tier 2 feature proposals committed this week (16 proposals for NIH funding and publication velocity) should substantially improve model quality next cycle.

Model quality
approval model informativeTrue
approval cv auc0.9219
approval label balance okTrue
approval label split{'positive_pct': 80.9, 'negative_pct': 19.1, 'note': 'Both classes above 10% threshold but moderately imbalanced'}
approval dominant featureregulatory_momentum_approval_count
approval quality noteCV AUC of 0.92 is high but the model is effectively a single-feature threshold on regulatory_momentum_approval_count, which dominates 192 of 199 predictions — the model is not learning nuanced patterns, it is counting prior approvals.
disruption model informativeTrue
disruption quality noteTwo features carry the model: regulatory_momentum_approval_count (0.270 importance) and shortage_risk_score (0.216). Pipeline density contributes negligibly (0.002). Policy risk and trial anomaly rate have zero importance. The disruption score is better described as an approval-and-shortage index than a true disruption risk model.
revenue model noteCMS spend trajectory is null for all 199 rows, so the revenue model is entirely driven by regulatory_momentum_approval_count and a trivial pipeline_density term. The 2yr CMS data lag caveat applies, but more critically, the CMS feature has no data at all this cycle.
Notable signals this week
KEYTRUDA Bladder Cancer approval probability 95.6% High approval probability aligns with Edge Discovery signal EOI-001 (dense competitive pipeline, 27 active trials). Model captures this signal via regulatory_momentum and high pipeline density.
OPDIVO Melanoma disruption risk 100.0% Maximum disruption score aligns with EOI-002 — BMS recall adds supply disruption risk on top of 5 cross-vertical approvals. Model captures the shortage signal, though it cannot distinguish recall-specific risk from general approval momentum.
VENCLEXTA Acute Myeloid Leukemia approval probability 96.1% High approval probability aligns with EOI-004 (new AML approval, AbbVie maintenance trial). Model correctly picks up the regulatory momentum signal but cannot capture the trial-specific convergence the edge agent identified.
AVASTIN Renal Cell Carcinoma approval probability 3.6% Suspiciously low approval probability for a drug the Edge Discovery agent flagged as active in RCC (EOI-005). Bevacizumab has approval_count=0 in the feature matrix, so the model assigns near-zero probability — the model misses the biosimilar competition signal the edge agent identified because it lacks a biosimilar entry feature.
ENHERTU Breast Cancer approval probability 85.2% Moderately high approval probability aligns with EOI-007 (ADC expanding indication footprint). Model picks up regulatory momentum but the disruption score is low (0.031) — the model does not capture the competitive threat Enhertu poses to traditional HER2 therapies because it lacks market-share or ADC penetration features.
Feature improvement proposals (3)
biosimilar entry count medium

Currently absent. The edge agent flagged biosimilar competition for bevacizumab in RCC (EOI-005) but the model has no feature to capture this. Add a count of FDA-approved biosimilars per molecule from the FDA Purple Book (https://www.fda.gov/drugs/biosimilars/biosimilar-product-information) which provides a downloadable list of approved biosimilar products. This would let the model distinguish originator drugs facing biosimilar erosion from those without biosimilar competition.

nih funding momentum usd per yr medium

Currently null for all 199 rows. The Tier 2 agent committed 8 proposals this week to fill this feature for Keytruda, Opdivo, Venclexta, Bortezomib, Enhertu, and Velcade. NIH Reporter v2 API (https://api.reporter.nih.gov/) provides grant award data by indication. Implementing the batch fetch for all 199 pairs would add a funding-trend signal that is independent of regulatory momentum and could break the single-feature dominance in the approval model.

publication velocity cagr low

Currently null for all 199 rows. The Tier 2 agent committed 8 proposals this week to fill this feature. PubMed E-utilities (https://www.ncbi.nlm.nih.gov/books/NBK25500/) provide publication counts by MeSH term. Computing a 3-year CAGR per indication would add a research-velocity signal that is distinct from trial density and could help the model distinguish indications with growing academic interest from those with static pipelines.

199
Drug × indication signals
66
High disruption (≥60%)
199
Training rows (in-sample)
Yes
Disruption RF trained
Model details & data freshness
Data freshness by vertical
VerticalSourceCadence
Academic research PubMed · NIH Reporter weekly
Drug discovery ChEMBL · Open Targets weekly
Trials Thread 2 cross-ref daily
FDA regulatory openFDA Drugs@FDA weekly
Sales (CMS) CMS Part D 2yr lag — amber always
Manufacturing openFDA enforcement weekly
Distribution HRSA 340B weekly
Government policy Fed Register · Congress weekly
Model metadata
Approval rank (relative — not calibrated)
LogisticRegression(C=1.0, L2)
Label = 1 if drug has any approval post-2018, 0 otherwise. In-sample split — not an external held-out dataset. CV AUC is indicative only.
Disruption risk
RandomForestClassifier(n_estimators=50, max_depth=4)
Labels constructed from observable KG signals (shortage + competitive entry). No validated ground truth.
Revenue trajectory index
Ridge(alpha=1.0)
CMS Part D data has 2yr lag. Treat output as directional index only.
Market entry timing
Empirical approval year distribution per indication
Distribution of approval years, not trial duration. Trial start dates not yet in KG.
Filter:
Signal table — sorted by disruption risk

Click any row to expand feature contributions. Hover evidence column header for tooltip. — in raw features = null (score reliability reduced).

Drug ↕ Indication ↕ Disruption risk ↕ Appr. rank (rel.) ⓘ ↕ Revenue index ↕ Approval yr (median) ↕ Data completeness ⓘ ↕
AKEEGA
ABIRATERONE ACETATE
 Prostate Cancer 98.1% 100.0%
100.0–100.0%
 9.96 2022 (n=33) 56% ▸
AKEEGA
ABIRATERONE ACETATE
 Ovarian Cancer 96.1% 100.0%
100.0–100.0%
 9.96 2020 (n=41) 56% ▸
LENALIDOMIDE
 Chronic Lymphocytic Leukemia 98.1% 100.0%
100.0–100.0%
 9.96 2025 (n=23) 56% ▸
LENALIDOMIDE
 Diffuse Large B-Cell Lymphoma 98.1% 100.0%
100.0–100.0%
 9.96 2026 (n=16) 56% ▸
LENALIDOMIDE
 Multiple Myeloma 97.1% 100.0%
100.0–100.0%
 9.96 2022 (n=29) 56% ▸
BORTEZOMIB
 Multiple Myeloma 100.0% 100.0%
100.0–100.0%
 8.97 2022 (n=29) 56% ▸
CARFILZOMIB
 Multiple Myeloma 100.0% 100.0%
100.0–100.0%
 5.98 2022 (n=29) 56% ▸
ENZALUTAMIDE
 Prostate Cancer 98.1% 100.0%
100.0–100.0%
 5.98 2022 (n=33) 56% ▸
CABAZITAXEL
 Prostate Cancer 98.1% 100.0%
100.0–100.0%
 6.98 2022 (n=33) 56% ▸
DOCETAXEL
 Head and Neck Cancer 98.4% 100.0%
100.0–100.0%
 9.96 2023 (n=25) 56% ▸
DOCETAXEL
 Gastric Cancer 97.1% 100.0%
100.0–100.0%
 9.96 2023 (n=66) 56% ▸
DOCETAXEL
 Prostate Cancer 98.1% 100.0%
100.0–100.0%
 9.96 2022 (n=33) 56% ▸
DOCETAXEL
 Breast Cancer 95.3% 100.0%
100.0–100.0%
 9.96 2023 (n=67) 56% ▸
DOCETAXEL
 Non-Small Cell Lung Cancer 95.5% 100.0%
100.0–100.0%
 9.96 2020 (n=50) 56% ▸
PACLITAXEL
 Gastric Cancer 97.1% 100.0%
100.0–100.0%
 8.97 2023 (n=66) 56% ▸
PACLITAXEL
 Ovarian Cancer 96.1% 100.0%
100.0–100.0%
 8.97 2020 (n=41) 56% ▸
PACLITAXEL
 Breast Cancer 95.3% 100.0%
100.0–100.0%
 8.96 2023 (n=67) 56% ▸
PACLITAXEL
 Non-Small Cell Lung Cancer 95.5% 100.0%
100.0–100.0%
 8.97 2020 (n=50) 56% ▸
IRINOTECAN HYDROCHLORIDE
 Colorectal Cancer 94.1% 100.0%
100.0–100.0%
 6.98 2022 (n=46) 56% ▸
GEMCITABINE HYDROCHLORIDE
 Bladder Cancer 94.5% 100.0%
100.0–100.0%
 9.96 2019 (n=15) 56% ▸
GEMCITABINE HYDROCHLORIDE
 Ovarian Cancer 96.1% 100.0%
100.0–100.0%
 9.96 2020 (n=41) 56% ▸
GEMCITABINE HYDROCHLORIDE
 Non-Small Cell Lung Cancer 95.5% 100.0%
100.0–100.0%
 9.96 2020 (n=50) 56% ▸
GEMCITABINE HYDROCHLORIDE
 Pancreatic Cancer 98.1% 100.0%
100.0–100.0%
 9.96 2019 (n=10) 56% ▸
CARAC
FLUOROURACIL
 Gastric Cancer 97.1% 100.0%
100.0–100.0%
 6.98 2023 (n=66) 56% ▸
CARAC
FLUOROURACIL
 Colorectal Cancer 94.1% 100.0%
100.0–100.0%
 6.98 2022 (n=46) 56% ▸
CARAC
FLUOROURACIL
 Head and Neck Cancer 98.4% 100.0%
100.0–100.0%
 6.98 2023 (n=25) 56% ▸
CARAC
FLUOROURACIL
 Breast Cancer 95.3% 100.0%
100.0–100.0%
 6.97 2023 (n=67) 56% ▸
CAPECITABINE
 Gastric Cancer 97.1% 100.0%
100.0–100.0%
 9.96 2023 (n=66) 56% ▸
CAPECITABINE
 Colorectal Cancer 94.1% 100.0%
100.0–100.0%
 9.96 2022 (n=46) 56% ▸
CAPECITABINE
 Breast Cancer 95.3% 100.0%
100.0–100.0%
 9.96 2023 (n=67) 56% ▸
OPDIVO
NIVOLUMAB
 Colorectal Cancer 100.0% 100.0%
100.0–100.0%
 4.99 2022 (n=46) 56% ▸
OPDIVO
NIVOLUMAB
 Non-Small Cell Lung Cancer 100.0% 100.0%
100.0–100.0%
 4.99 2020 (n=50) 56% ▸
IMBRUVICA
IBRUTINIB
 Chronic Lymphocytic Leukemia 94.1% 100.0%
100.0–100.0%
 4.99 2025 (n=23) 56% ▸
OXALIPLATIN
 Gastric Cancer 97.1% 100.0%
100.0–100.0%
 4.99 2023 (n=66) 56% ▸
OXALIPLATIN
 Colorectal Cancer 94.1% 100.0%
100.0–100.0%
 4.99 2022 (n=46) 56% ▸
OPDIVO
NIVOLUMAB
 Renal Cell Carcinoma 100.0% 100.0%
100.0–100.0%
 4.99 2022 (n=14) 56% ▸
OPDIVO
NIVOLUMAB
 Head and Neck Cancer 100.0% 100.0%
100.0–100.0%
 4.99 2023 (n=25) 56% ▸
OPDIVO
NIVOLUMAB
 Melanoma 100.0% 100.0%
100.0–100.0%
 4.99 2024 (n=8) 56% ▸
OPDIVO
NIVOLUMAB
 Gastric Cancer 100.0% 100.0%
100.0–100.0%
 4.99 2023 (n=66) 56% ▸
OPDIVO
NIVOLUMAB
 Hepatocellular Carcinoma 100.0% 100.0%
100.0–100.0%
 4.99 2022 (n=15) 56% ▸
IBRANCE
PALBOCICLIB
 Breast Cancer 68.7% 99.5%
99.3–99.7%
 2.99 2023 (n=67) 56% ▸
VERZENIO
ABEMACICLIB
 Breast Cancer 9.0% 97.2%
95.9–98.0%
 2.00 2023 (n=67) 56% ▸
LYNPARZA
OLAPARIB
 Breast Cancer 9.0% 97.2%
96.1–98.0%
 2.00 2023 (n=67) 56% ▸
KEYTRUDA
PEMBROLIZUMAB
 Breast Cancer 83.7% 96.6%
95.3–97.6%
 2.00 2023 (n=67) 56% ▸
LYNPARZA
OLAPARIB
 Ovarian Cancer 15.1% 96.2%
94.5–97.3%
 2.00 2020 (n=41) 56% ▸
ZEJULA
NIRAPARIB TOSYLATE
 Ovarian Cancer 15.1% 96.2%
95.1–97.3%
 2.00 2020 (n=41) 56% ▸
VENCLEXTA
VENETOCLAX
 Acute Myeloid Leukemia 12.2% 96.1%
94.6–97.3%
 2.00 2026 (n=2) 56% ▸
VENCLEXTA
VENETOCLAX
 Chronic Lymphocytic Leukemia 12.5% 95.9%
94.4–97.4%
 2.00 2025 (n=23) 56% ▸
KEYTRUDA
PEMBROLIZUMAB
 Non-Small Cell Lung Cancer 96.3% 95.8%
93.8–97.0%
 2.00 2020 (n=50) 56% ▸
TECENTRIQ
ATEZOLIZUMAB
 Non-Small Cell Lung Cancer 96.3% 95.8%
93.9–97.0%
 2.00 2020 (n=50) 56% ▸
KEYTRUDA
PEMBROLIZUMAB
 Colorectal Cancer 98.0% 95.7%
94.0–96.9%
 2.00 2022 (n=46) 56% ▸
KEYTRUDA
PEMBROLIZUMAB
 Bladder Cancer 99.4% 95.6%
94.0–97.0%
 2.00 2019 (n=15) 56% ▸
TECENTRIQ
ATEZOLIZUMAB
 Bladder Cancer 99.4% 95.6%
94.2–96.8%
 2.00 2019 (n=15) 56% ▸
KEYTRUDA
PEMBROLIZUMAB
 Gastric Cancer 99.4% 95.5%
93.9–97.0%
 2.00 2023 (n=66) 56% ▸
KEYTRUDA
PEMBROLIZUMAB
 Hepatocellular Carcinoma 99.4% 95.5%
93.6–96.7%
 2.00 2022 (n=15) 56% ▸
KEYTRUDA
PEMBROLIZUMAB
 Head and Neck Cancer 99.4% 95.5%
93.8–96.9%
 2.00 2023 (n=25) 56% ▸
KEYTRUDA
PEMBROLIZUMAB
 Melanoma 92.2% 95.4%
93.5–96.8%
 2.00 2024 (n=8) 56% ▸
RITUXAN HYCELA
RITUXIMAB
 Diffuse Large B-Cell Lymphoma 91.1% 95.1%
92.7–96.3%
 2.00 2026 (n=16) 56% ▸
RITUXAN HYCELA
RITUXIMAB
 Chronic Lymphocytic Leukemia 90.4% 95.1%
93.2–96.3%
 2.00 2025 (n=23) 56% ▸
TRAZIMERA
TRASTUZUMAB-QYYP
 Breast Cancer 3.1% 85.2%
79.7–89.3%
 1.00 2023 (n=67) 56% ▸
HERZUMA
TRASTUZUMAB-PKRB
 Breast Cancer 3.1% 85.2%
80.0–89.2%
 1.00 2023 (n=67) 56% ▸
ONTRUZANT
TRASTUZUMAB-DTTB
 Breast Cancer 3.1% 85.2%
79.4–89.4%
 1.00 2023 (n=67) 56% ▸
HERCEPTIN HYLECTA
TRASTUZUMAB AND HYALURONIDASE-OYSK
 Breast Cancer 3.1% 85.2%
80.1–88.8%
 1.00 2023 (n=67) 56% ▸
ENHERTU
FAM-TRASTUZUMAB DERUXTECAN-NXKI
 Breast Cancer 3.1% 85.2%
79.3–89.8%
 1.00 2023 (n=67) 56% ▸
KADCYLA
ADO-TRASTUZUMAB EMTANSINE
 Breast Cancer 3.1% 85.2%
80.0–89.2%
 1.00 2023 (n=67) 56% ▸
PHESGO
PERTUZUMAB, TRASTUZUMAB, AND HYALURONIDASE-ZZXF
 Breast Cancer 3.1% 85.2%
79.9–89.4%
 1.00 2023 (n=67) 56% ▸
HERCESSI
TRASTUZUMAB-STRF
 Breast Cancer 3.1% 85.2%
79.6–88.6%
 1.00 2023 (n=67) 56% ▸
KANJINTI
TRASTUZUMAB-ANNS
 Breast Cancer 3.1% 85.2%
80.0–89.4%
 1.00 2023 (n=67) 56% ▸
POHERDY
PERTUZUMAB-DPZB
 Breast Cancer 3.1% 85.2%
79.2–89.5%
 1.00 2023 (n=67) 56% ▸
ZIRABEV
BEVACIZUMAB-BVZR
 Breast Cancer 3.1% 85.2%
80.2–89.6%
 1.00 2023 (n=67) 56% ▸
JOBEVNE
BEVACIZUMAB-NWGD
 Breast Cancer 3.1% 85.2%
80.2–89.0%
 1.00 2023 (n=67) 56% ▸
AVZIVI
BEVACIZUMAB-TNJN
 Breast Cancer 3.1% 85.2%
80.4–89.7%
 1.00 2023 (n=67) 56% ▸
ALYMSYS
BEVACIZUMAB-MALY
 Breast Cancer 3.1% 85.2%
80.1–88.6%
 1.00 2023 (n=67) 56% ▸
VEGZELMA
BEVACIZUMAB-ADCD
 Breast Cancer 3.1% 85.2%
79.8–89.5%
 1.00 2023 (n=67) 56% ▸
LYTENAVA
BEVACIZUMAB-VIKG
 Breast Cancer 3.1% 85.2%
80.0–89.0%
 1.00 2023 (n=67) 56% ▸
MVASI
BEVACIZUMAB-AWWB
 Breast Cancer 3.1% 85.2%
80.5–89.0%
 1.00 2023 (n=67) 56% ▸
KISQALI FEMARA CO-PACK (COPACKAGED)
LETROZOLE
 Breast Cancer 3.1% 85.2%
80.9–89.5%
 1.00 2023 (n=67) 56% ▸
KISQALI
RIBOCICLIB SUCCINATE
 Breast Cancer 3.1% 85.2%
80.7–88.7%
 1.00 2023 (n=67) 56% ▸
PERJETA
PERTUZUMAB
 Breast Cancer 85.7% 82.5%
77.5–87.1%
 1.00 2023 (n=67) 56% ▸
TECENTRIQ HYBREZA
ATEZOLIZUMAB AND HYALURONIDASE-TQJS
 Non-Small Cell Lung Cancer 4.3% 81.9%
75.3–86.7%
 1.01 2020 (n=50) 56% ▸
ZIRABEV
BEVACIZUMAB-BVZR
 Non-Small Cell Lung Cancer 4.3% 81.9%
76.0–86.6%
 1.01 2020 (n=50) 56% ▸
JOBEVNE
BEVACIZUMAB-NWGD
 Non-Small Cell Lung Cancer 4.3% 81.9%
75.5–86.7%
 1.01 2020 (n=50) 56% ▸
AVZIVI
BEVACIZUMAB-TNJN
 Non-Small Cell Lung Cancer 4.3% 81.9%
75.7–86.5%
 1.01 2020 (n=50) 56% ▸
ALYMSYS
BEVACIZUMAB-MALY
 Non-Small Cell Lung Cancer 4.3% 81.9%
76.5–86.5%
 1.01 2020 (n=50) 56% ▸
VEGZELMA
BEVACIZUMAB-ADCD
 Non-Small Cell Lung Cancer 4.3% 81.9%
76.3–86.7%
 1.01 2020 (n=50) 56% ▸
LYTENAVA
BEVACIZUMAB-VIKG
 Non-Small Cell Lung Cancer 4.3% 81.9%
77.2–86.4%
 1.01 2020 (n=50) 56% ▸
MVASI
BEVACIZUMAB-AWWB
 Non-Small Cell Lung Cancer 4.3% 81.9%
76.2–86.8%
 1.01 2020 (n=50) 56% ▸
TAGRISSO
OSIMERTINIB MESYLATE
 Non-Small Cell Lung Cancer 4.3% 81.9%
76.2–86.5%
 1.01 2020 (n=50) 56% ▸
ALECENSA
ALECTINIB HYDROCHLORIDE
 Non-Small Cell Lung Cancer 4.3% 81.9%
76.1–87.0%
 1.01 2020 (n=50) 56% ▸
YERVOY
IPILIMUMAB
 Colorectal Cancer 4.9% 81.6%
75.0–86.0%
 1.01 2022 (n=46) 56% ▸
ZIRABEV
BEVACIZUMAB-BVZR
 Colorectal Cancer 4.9% 81.6%
76.0–86.7%
 1.01 2022 (n=46) 56% ▸
JOBEVNE
BEVACIZUMAB-NWGD
 Colorectal Cancer 4.9% 81.6%
75.7–86.7%
 1.01 2022 (n=46) 56% ▸
AVZIVI
BEVACIZUMAB-TNJN
 Colorectal Cancer 4.9% 81.6%
75.3–86.7%
 1.01 2022 (n=46) 56% ▸
ALYMSYS
BEVACIZUMAB-MALY
 Colorectal Cancer 4.9% 81.6%
74.1–86.0%
 1.01 2022 (n=46) 56% ▸
VEGZELMA
BEVACIZUMAB-ADCD
 Colorectal Cancer 4.9% 81.6%
75.6–85.6%
 1.01 2022 (n=46) 56% ▸
LYTENAVA
BEVACIZUMAB-VIKG
 Colorectal Cancer 4.9% 81.6%
75.0–86.1%
 1.01 2022 (n=46) 56% ▸
MVASI
BEVACIZUMAB-AWWB
 Colorectal Cancer 4.9% 81.6%
75.9–86.2%
 1.01 2022 (n=46) 56% ▸
TECENTRIQ HYBREZA
ATEZOLIZUMAB AND HYALURONIDASE-TQJS
 Bladder Cancer 5.2% 81.3%
74.9–85.8%
 1.01 2019 (n=15) 56% ▸
TRAZIMERA
TRASTUZUMAB-QYYP
 Gastric Cancer 1.8% 81.1%
74.8–86.3%
 1.01 2023 (n=66) 56% ▸
HERZUMA
TRASTUZUMAB-PKRB
 Gastric Cancer 1.8% 81.1%
75.7–85.8%
 1.01 2023 (n=66) 56% ▸
ONTRUZANT
TRASTUZUMAB-DTTB
 Gastric Cancer 1.8% 81.1%
74.7–84.9%
 1.01 2023 (n=66) 56% ▸
HERCEPTIN HYLECTA
TRASTUZUMAB AND HYALURONIDASE-OYSK
 Gastric Cancer 1.8% 81.1%
74.6–86.0%
 1.01 2023 (n=66) 56% ▸
ENHERTU
FAM-TRASTUZUMAB DERUXTECAN-NXKI
 Gastric Cancer 1.8% 81.1%
75.5–86.2%
 1.01 2023 (n=66) 56% ▸
KADCYLA
ADO-TRASTUZUMAB EMTANSINE
 Gastric Cancer 1.8% 81.1%
75.3–86.0%
 1.01 2023 (n=66) 56% ▸
PHESGO
PERTUZUMAB, TRASTUZUMAB, AND HYALURONIDASE-ZZXF
 Gastric Cancer 1.8% 81.1%
75.2–85.7%
 1.01 2023 (n=66) 56% ▸
HERCESSI
TRASTUZUMAB-STRF
 Gastric Cancer 1.8% 81.1%
74.5–85.7%
 1.01 2023 (n=66) 56% ▸
KANJINTI
TRASTUZUMAB-ANNS
 Gastric Cancer 1.8% 81.1%
75.2–85.8%
 1.01 2023 (n=66) 56% ▸
ZIRABEV
BEVACIZUMAB-BVZR
 Gastric Cancer 1.8% 81.1%
73.9–85.8%
 1.01 2023 (n=66) 56% ▸
JOBEVNE
BEVACIZUMAB-NWGD
 Gastric Cancer 1.8% 81.1%
74.9–85.7%
 1.01 2023 (n=66) 56% ▸
AVZIVI
BEVACIZUMAB-TNJN
 Gastric Cancer 1.8% 81.1%
75.8–86.1%
 1.01 2023 (n=66) 56% ▸
ALYMSYS
BEVACIZUMAB-MALY
 Gastric Cancer 1.8% 81.1%
73.8–85.4%
 1.01 2023 (n=66) 56% ▸
VEGZELMA
BEVACIZUMAB-ADCD
 Gastric Cancer 1.8% 81.1%
75.4–85.8%
 1.01 2023 (n=66) 56% ▸
LYTENAVA
BEVACIZUMAB-VIKG
 Gastric Cancer 1.8% 81.1%
74.9–86.0%
 1.01 2023 (n=66) 56% ▸
MVASI
BEVACIZUMAB-AWWB
 Gastric Cancer 1.8% 81.1%
74.0–85.4%
 1.01 2023 (n=66) 56% ▸
DARZALEX FASPRO
DARATUMUMAB AND HYALURONIDASE-FIHJ
 Multiple Myeloma 1.8% 81.1%
76.0–85.3%
 1.01 2022 (n=29) 56% ▸
DARZALEX
DARATUMUMAB
 Multiple Myeloma 1.8% 81.1%
74.3–86.0%
 1.01 2022 (n=29) 56% ▸
NINLARO
IXAZOMIB CITRATE
 Multiple Myeloma 1.8% 81.1%
74.9–85.6%
 1.01 2022 (n=29) 56% ▸
EMPLICITI
ELOTUZUMAB
 Multiple Myeloma 1.8% 81.1%
75.6–85.8%
 1.01 2022 (n=29) 56% ▸
ZIRABEV
BEVACIZUMAB-BVZR
 Hepatocellular Carcinoma 1.8% 81.0%
75.0–86.1%
 1.01 2022 (n=15) 56% ▸
JOBEVNE
BEVACIZUMAB-NWGD
 Hepatocellular Carcinoma 1.8% 81.0%
74.4–85.3%
 1.01 2022 (n=15) 56% ▸
AVZIVI
BEVACIZUMAB-TNJN
 Hepatocellular Carcinoma 1.8% 81.0%
76.1–85.9%
 1.01 2022 (n=15) 56% ▸
ALYMSYS
BEVACIZUMAB-MALY
 Hepatocellular Carcinoma 1.8% 81.0%
74.8–85.9%
 1.01 2022 (n=15) 56% ▸
VEGZELMA
BEVACIZUMAB-ADCD
 Hepatocellular Carcinoma 1.8% 81.0%
74.7–85.9%
 1.01 2022 (n=15) 56% ▸
LYTENAVA
BEVACIZUMAB-VIKG
 Hepatocellular Carcinoma 1.8% 81.0%
74.3–85.5%
 1.01 2022 (n=15) 56% ▸
MVASI
BEVACIZUMAB-AWWB
 Hepatocellular Carcinoma 1.8% 81.0%
74.4–85.9%
 1.01 2022 (n=15) 56% ▸
ZIRABEV
BEVACIZUMAB-BVZR
 Ovarian Cancer 1.7% 80.6%
74.7–85.2%
 1.01 2020 (n=41) 56% ▸
JOBEVNE
BEVACIZUMAB-NWGD
 Ovarian Cancer 1.7% 80.6%
74.6–85.8%
 1.01 2020 (n=41) 56% ▸
AVZIVI
BEVACIZUMAB-TNJN
 Ovarian Cancer 1.7% 80.6%
74.1–86.8%
 1.01 2020 (n=41) 56% ▸
ALYMSYS
BEVACIZUMAB-MALY
 Ovarian Cancer 1.7% 80.6%
74.8–85.6%
 1.01 2020 (n=41) 56% ▸
VEGZELMA
BEVACIZUMAB-ADCD
 Ovarian Cancer 1.7% 80.6%
73.8–86.4%
 1.01 2020 (n=41) 56% ▸
LYTENAVA
BEVACIZUMAB-VIKG
 Ovarian Cancer 1.7% 80.6%
75.5–86.1%
 1.01 2020 (n=41) 56% ▸
MVASI
BEVACIZUMAB-AWWB
 Ovarian Cancer 1.7% 80.6%
74.4–85.3%
 1.01 2020 (n=41) 56% ▸
YERVOY
IPILIMUMAB
 Melanoma 0.6% 80.5%
74.4–86.1%
 1.01 2024 (n=8) 56% ▸
YERVOY
IPILIMUMAB
 Renal Cell Carcinoma 0.6% 79.8%
73.6–85.0%
 1.01 2022 (n=14) 56% ▸
ZIRABEV
BEVACIZUMAB-BVZR
 Renal Cell Carcinoma 0.6% 79.8%
74.2–84.6%
 1.01 2022 (n=14) 56% ▸
JOBEVNE
BEVACIZUMAB-NWGD
 Renal Cell Carcinoma 0.6% 79.8%
73.4–84.7%
 1.01 2022 (n=14) 56% ▸
AVZIVI
BEVACIZUMAB-TNJN
 Renal Cell Carcinoma 0.6% 79.8%
73.6–85.8%
 1.01 2022 (n=14) 56% ▸
ALYMSYS
BEVACIZUMAB-MALY
 Renal Cell Carcinoma 0.6% 79.8%
74.2–84.9%
 1.01 2022 (n=14) 56% ▸
VEGZELMA
BEVACIZUMAB-ADCD
 Renal Cell Carcinoma 0.6% 79.8%
73.3–85.4%
 1.01 2022 (n=14) 56% ▸
LYTENAVA
BEVACIZUMAB-VIKG
 Renal Cell Carcinoma 0.6% 79.8%
72.8–84.6%
 1.01 2022 (n=14) 56% ▸
MVASI
BEVACIZUMAB-AWWB
 Renal Cell Carcinoma 0.6% 79.8%
72.8–85.3%
 1.01 2022 (n=14) 56% ▸
TRUXIMA
RITUXIMAB-ABBS
 Diffuse Large B-Cell Lymphoma 0.3% 79.6%
73.4–84.7%
 1.01 2026 (n=16) 56% ▸
RUXIENCE
RITUXIMAB-PVVR
 Diffuse Large B-Cell Lymphoma 0.3% 79.6%
74.1–84.9%
 1.01 2026 (n=16) 56% ▸
RIABNI
RITUXIMAB-ARRX
 Diffuse Large B-Cell Lymphoma 0.3% 79.6%
73.3–85.3%
 1.01 2026 (n=16) 56% ▸
ZIMRIXBY
RITUXIMAB-CDXX
 Diffuse Large B-Cell Lymphoma 0.3% 79.6%
73.5–85.2%
 1.01 2026 (n=16) 56% ▸
TRUXIMA
RITUXIMAB-ABBS
 Chronic Lymphocytic Leukemia 0.2% 79.5%
72.3–84.8%
 1.01 2025 (n=23) 56% ▸
RUXIENCE
RITUXIMAB-PVVR
 Chronic Lymphocytic Leukemia 0.2% 79.5%
72.7–84.4%
 1.01 2025 (n=23) 56% ▸
RIABNI
RITUXIMAB-ARRX
 Chronic Lymphocytic Leukemia 0.2% 79.5%
73.0–84.2%
 1.01 2025 (n=23) 56% ▸
ZIMRIXBY
RITUXIMAB-CDXX
 Chronic Lymphocytic Leukemia 0.2% 79.5%
73.4–85.4%
 1.01 2025 (n=23) 56% ▸
IMFINZI
DURVALUMAB
 Non-Small Cell Lung Cancer 88.9% 78.8%
71.2–83.6%
 1.01 2020 (n=50) 56% ▸
ERBITUX
CETUXIMAB
 Colorectal Cancer 90.8% 78.5%
71.7–83.8%
 1.01 2022 (n=46) 56% ▸
ERBITUX
CETUXIMAB
 Head and Neck Cancer 87.3% 77.7%
70.7–82.9%
 1.01 2023 (n=25) 56% ▸
HERCEPTIN
TRASTUZUMAB
 Breast Cancer 87.7% 76.2%
69.9–82.2%
 1.00 2023 (n=67) 56% ▸
HERCEPTIN
TRASTUZUMAB
 Gastric Cancer 88.8% 70.6%
63.2–77.5%
 1.01 2023 (n=66) 56% ▸
Ibrance
 Breast Cancer 1.9% 48.5%
39.4–58.1%
 0.01 2023 (n=67) 56% ▸
Kisqali
 Breast Cancer 1.9% 48.5%
41.1–58.3%
 0.01 2023 (n=67) 56% ▸
Verzenio
 Breast Cancer 1.9% 48.5%
39.9–56.6%
 0.01 2023 (n=67) 56% ▸
Lynparza
 Breast Cancer 1.9% 48.5%
39.5–57.6%
 0.01 2023 (n=67) 56% ▸
Trodelvy
 Breast Cancer 1.9% 48.5%
38.0–57.6%
 0.01 2023 (n=67) 56% ▸
Enhertu
 Breast Cancer 1.9% 48.5%
41.5–57.6%
 0.01 2023 (n=67) 56% ▸
Kadcyla
 Breast Cancer 1.9% 48.5%
40.6–58.3%
 0.01 2023 (n=67) 56% ▸
Keytruda
 Non-Small Cell Lung Cancer 2.2% 42.6%
33.7–51.3%
 0.01 2020 (n=50) 56% ▸
Opdivo
 Non-Small Cell Lung Cancer 2.2% 42.6%
32.0–51.6%
 0.01 2020 (n=50) 56% ▸
Tecentriq
 Non-Small Cell Lung Cancer 2.2% 42.6%
33.4–52.4%
 0.01 2020 (n=50) 56% ▸
Imfinzi
 Non-Small Cell Lung Cancer 2.2% 42.6%
35.1–51.2%
 0.01 2020 (n=50) 56% ▸
Tagrisso
 Non-Small Cell Lung Cancer 2.2% 42.6%
35.5–50.7%
 0.01 2020 (n=50) 56% ▸
Keytruda
 Bladder Cancer 2.6% 41.8%
33.5–50.0%
 0.01 2019 (n=15) 56% ▸
Tecentriq
 Bladder Cancer 2.6% 41.8%
32.7–50.1%
 0.01 2019 (n=15) 56% ▸
Keytruda
 Gastric Cancer 1.2% 41.4%
33.4–49.4%
 0.01 2023 (n=66) 56% ▸
Darzalex
 Multiple Myeloma 1.2% 41.4%
31.7–49.5%
 0.01 2022 (n=29) 56% ▸
Revlimid
 Multiple Myeloma 1.2% 41.4%
33.7–50.2%
 0.01 2022 (n=29) 56% ▸
Pomalyst
 Multiple Myeloma 1.2% 41.4%
33.5–50.5%
 0.01 2022 (n=29) 56% ▸
Velcade
 Multiple Myeloma 1.2% 41.4%
32.6–51.0%
 0.01 2022 (n=29) 56% ▸
Kyprolis
 Multiple Myeloma 1.2% 41.4%
33.7–49.6%
 0.01 2022 (n=29) 56% ▸
Enhertu
 Gastric Cancer 1.2% 41.4%
33.5–51.8%
 0.01 2023 (n=66) 56% ▸
Opdivo
 Hepatocellular Carcinoma 1.0% 41.1%
32.7–49.6%
 0.01 2022 (n=15) 56% ▸
Keytruda
 Head and Neck Cancer 1.0% 41.0%
32.4–49.1%
 0.01 2023 (n=25) 56% ▸
Opdivo
 Head and Neck Cancer 1.0% 41.0%
33.2–49.6%
 0.01 2023 (n=25) 56% ▸
Lynparza
 Ovarian Cancer 0.9% 40.6%
32.6–48.0%
 0.01 2020 (n=41) 56% ▸
Zejula
 Ovarian Cancer 0.9% 40.6%
33.8–48.9%
 0.01 2020 (n=41) 56% ▸
Keytruda
 Melanoma 0.1% 40.4%
31.9–49.0%
 0.01 2024 (n=8) 56% ▸
Opdivo
 Melanoma 0.1% 40.4%
31.8–50.2%
 0.01 2024 (n=8) 56% ▸
Yervoy
 Melanoma 0.1% 40.4%
32.5–50.4%
 0.01 2024 (n=8) 56% ▸
Venclexta
 Acute Myeloid Leukemia 0.1% 40.1%
32.9–51.1%
 0.01 2026 (n=2) 56% ▸
Opdivo
 Renal Cell Carcinoma 0.1% 39.4%
30.9–46.8%
 0.01 2022 (n=14) 56% ▸
Calquence
 Chronic Lymphocytic Leukemia 0.0% 38.9%
30.2–47.9%
 0.01 2025 (n=23) 56% ▸
Imbruvica
 Chronic Lymphocytic Leukemia 0.0% 38.9%
32.0–47.7%
 0.01 2025 (n=23) 56% ▸
Venclexta
 Chronic Lymphocytic Leukemia 0.0% 38.9%
30.1–47.9%
 0.01 2025 (n=23) 56% ▸
Zytiga
 Prostate Cancer 0.0% 38.6%
31.4–46.0%
 0.01 2022 (n=33) 56% ▸
Xtandi
 Prostate Cancer 0.0% 38.6%
31.6–47.4%
 0.01 2022 (n=33) 56% ▸
Nubeqa
 Prostate Cancer 0.0% 38.6%
29.4–47.2%
 0.01 2022 (n=33) 56% ▸
Erleada
 Prostate Cancer 0.0% 38.6%
29.5–46.9%
 0.01 2022 (n=33) 56% ▸
AVASTIN
BEVACIZUMAB
 Breast Cancer 87.7% 5.1%
3.8–7.0%
 1.00 2023 (n=67) 56% ▸
AVASTIN
BEVACIZUMAB
 Non-Small Cell Lung Cancer 88.9% 4.1%
2.8–5.8%
 1.01 2020 (n=50) 56% ▸
AVASTIN
BEVACIZUMAB
 Colorectal Cancer 90.8% 4.0%
2.8–5.5%
 1.01 2022 (n=46) 56% ▸
AVASTIN
BEVACIZUMAB
 Gastric Cancer 90.8% 3.9%
2.5–5.3%
 1.01 2023 (n=66) 56% ▸
AVASTIN
BEVACIZUMAB
 Hepatocellular Carcinoma 91.3% 3.9%
2.8–5.3%
 1.01 2022 (n=15) 56% ▸
AVASTIN
BEVACIZUMAB
 Ovarian Cancer 87.3% 3.8%
2.6–5.2%
 1.01 2020 (n=41) 56% ▸
AVASTIN
BEVACIZUMAB
 Renal Cell Carcinoma 86.6% 3.6%
2.5–5.3%
 1.01 2022 (n=14) 56% ▸